A daily pill for senior dogs is moving close to a rare line in veterinary medicine. It is not designed for fleas, pain, or one specific disease. It is aimed at lifespan itself.
Loyal, the San Francisco biotech founded by Celine Halioua, is developing LOY-002 for dogs at least 10 years old and weighing 14 pounds or more, People reports.
The promise is simple enough to understand and hard to measure emotionally. Loyal is not claiming it can make dogs immortal. The goal is to extend healthy life before frailty, cancer, heart disease, and cognitive decline narrow a dog’s world. In February 2025, the FDA’s Center for Veterinary Medicine recognized the drug as having a reasonable expectation of effectiveness, The Washington Post reports.
A new dog longevity pill could soon reach veterinarians.
How The Pill Is Supposed To Work
LOY-002 focuses on metabolic changes that come with age. As dogs grow older, their bodies can lose some ability to handle insulin and energy use cleanly. Loyal’s approach aims to blunt that age-related dysfunction before it feeds a wider pattern of decline, The Guardian reports.
The idea has roots in earlier dog research. A 14-year Labrador retriever study found that dogs fed 25% less than their littermates lived about 15% longer on average. LOY-002 tries to capture some of that metabolic benefit without asking families to keep an old dog on a years-long restricted diet.
LOY-002 is being developed for senior dogs.
Why Dogs Are At The Center Of Longevity Science
Dogs age in ways that feel painfully familiar. They get cancer. They develop heart trouble. They slow down, forget routines, and lose confidence in their own bodies. They also share our homes, schedules, food environments, and stressors in ways lab animals do not. That makes them valuable partners in the search for healthier old age, The Guardian reports.
Loyal is not alone. The Dog Aging Project has tested rapamycin, a drug already used in human medicine, to see whether it can improve heart and cognitive health in dogs. These efforts do not prove that human lifespan drugs are near. They do show why dogs may become the first large-scale bridge between lab longevity science and daily life.
The FDA Path Still Matters
Conditional approval does not mean full proof. The FDA says a conditionally approved animal drug must be safe, properly manufactured, and reasonably expected to work while the company gathers stronger evidence for full approval.
Loyal says its STAY study includes 1,300 dogs across veterinary clinics in the United States, with placebo controls and long-term follow-up.
Dogs may become the first real test case for lifespan medicine.
More Years May Bring Harder Choices
If LOY-002 reaches clinics, the science will only be part of the story. Halioua has said she wants the drug to cost less than $100 a month, The Washington Post reports. For many families, that will still be a real bill. It could also create a new kind of guilt: the fear that saying no to a pill means saying no to more time.
The emotional stakes are clear. Dogs usually leave first, and that is part of the ache built into loving them. If a pill can add healthy years, many owners will want it. But longer life will also bring more medical decisions, more cost, and more pressure to define what a good old age should look like.
As The Atlantic reports, the future of dog longevity may change not just how long pets live, but how humans carry the responsibility of keeping them here.
